Breathing innovation into nasal drug delivery

The nose offers great potential as a patient-friendly pathway for local and systemic drug delivery. Our expertise and technical capabilities in the development and manufacturing of nasal drug products are designed to ensure that potential is realised for pharma partners.

Key services for pharmaceutical partners

  • Nasal spray manufacturing capabilities

    Our broad expertise in nasal drug delivery spans the entire product development cycle from formulation science to scale-up manufacture. Whether working with unit-dose, bi-dose or multi-dose products (preserved and sterile/non-preserved), the capabilities offered by our skilled in-house scientists and engineers ensures we can support any nasal project at any stage.

  • Nasal spray testing

    Equipped with a state-of-the-art laboratory, we have the capabilities to conduct a wide range of nasal spray testing services across unit-dose, bi-dose and multi-dose devices, covering everything from particle-size distribution to plume geometry. The combination of detailed spray characterisation and decades of experience enable us to enhance and accelerate product development.

  • Nasal spray development

    We are a specialist CDMO for nasal drug products, and our experience in the sector runs deep throughout the organisation. That means our partners can lean on our authoritative knowledge to guide and advance projects at any stage, from initial concept and testing through to device selection and commercialisation.

  • Site transfer

    Balancing rigorous structure with the ability to flex manufacturing capacity, we can support the seamless transfer of intranasal products currently in commercial production. The process is closely monitored and managed by our experienced project managers, who are assigned to ensure project deadlines are met and transition to the facility is completed smoothly.

  • Aseptic filling

    Our expertise in aseptic filling perfectly complements our device development services. Supported by advanced contamination control strategies and enhanced by automated inspection systems, our filling operations meet the highest regulatory requirements. We are equipped to handle a broad spectrum of sterile manufacturing needs, including small molecules, biologics, potent compounds and controlled substances (DEA Schedule I–V).

  • Packaging

    Our flexible, customisable secondary packaging solutions ensure the finishing touch is applied at the end of the manufacturing process. Packaging options are tailored to each particular nasal drug product, whether in the form of blister packaging for micro-dose devices or automated cartoning. We ensure the end result delivers on all requirements, from data serialisation and product security to brand promotion.

Key benefits for patients

  • Convenient, needle-free drug delivery

  • Local and systemic acting

  • Rapid onset

  • Improved bioavailability

  • Bypasses problems with oral delivery

Aseptic Filling

In the manufacturing of sterile injectable drug products, quality and safety are paramount. Pharma companies must be able to rely on a trusted partner with the knowledge and capabilities to deliver service excellence in compliance with the latest regulatory standards.
At LTS, we have the capacity, expertise and experience to support a full spectrum of aseptic processing and sterilization services for products including small molecules, biologics, controlled substances (DEA Schedule I-V).
Our modern filling operations integrate advanced contamination control strategies and highly automated systems for inspection and packaging, ensuring consistent quality, efficiency, and reliable product release. Each year, multiple inspections by customers and international regulatory agencies confirm our adherence to the highest standards – reinforcing our proven track record in sterile injectables.

Features of filling lines

  • IMA Extrema Filler

  • IMA SteriFil Filler

  • High-speed filling

  • Small-batch filling: Clinical trial and development batches

  • Glass vials: 2, 5, 10, 20, 50, and 100 mL

  • In-line vial washing and depyrogenation

Our core products

Our capabilities span both development and commercial scale manufacturing of unit dose, bi dose, and multi dose nasal sprays, all produced in state of the art, environmentally controlled facilities. With a strong track record of regulatory approvals, we can seamlessly onboard projects at any point in their lifecycle—from early concept development and formulation optimization to clinical manufacturing and the transfer of established commercial products.

Micro Dose nasal spray

Unit-dose nasal spray

This patient-ready, primeless device precisely delivers a single dose via one-handed actuation. The drug product is filled and secured within a speciality micro glass vial prior to product assembly, with a standard 100μl (microliter) dose. Micro Dose is suitable for both local and systemic therapies and can support effective lifecycle management strategies for existing brands through the addition of its simple, 360° functionality.

Bi-dose nasal spray

Enabling the precision delivery of up to 200μl of drug product to the patient via two nasal sprays. In the case of both the bi-dose and unit-dose products, vial stoppering is critical to device performance, and we ensure it is closely controlled through the provision of both mechanical and vacuum stoppering at clinical and commercial scale.
Multi Dose

Multi-dose nasal spray

Comprehensive manufacturing capabilities to support the production of multi-dose devices that consistently and repeatedly deliver an accurate measured dose. Our environmentally controlled filling facilities ensure both preserved and sterile (non-preserved) multi-dose formulations are catered for